Molteni Purchase Agreement (Details Textual) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Aug. 03, 2018
USD ($)
|
Mar. 31, 2019
USD ($)
|
Sep. 30, 2018
USD ($)
|
Jun. 30, 2018
USD ($)
|
Dec. 31, 2018
USD ($)
|
Dec. 31, 2018
EUR (€)
|
Dec. 31, 2017
USD ($)
|
Dec. 31, 2016
USD ($)
|
Sep. 18, 2018
$ / shares
|
Aug. 03, 2018
EUR (€)
|
|
| Purchase Agreement [Line Items] | ||||||||||
| Proceeds from Sale of Productive Assets | $ 2,400,000 | € 2,000,000 | ||||||||
| Revenue Recognition Milestone Methods Description | receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties. | receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory ranging in percentage from the low-teens to the mid-twenties. | ||||||||
| Debt Instrument, Interest Rate Terms | In the event the EMA has not granted marketing approval by December 31, 2019, the Convertible Loan will become due and payable, together with accrued interest at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum. | |||||||||
| Long-term Purchase Commitment, Milestones | On August 3, 2018, we entered into an amendment (the “Amendment”) to the Purchase Agreement with Molteni. Under the Amendment, Molteni made an immediate payment to us of €950,000 (approximately $1.1 million) and committed to make a convertible loan to us of €550,000 (approximately $0.6 million) provided we have submitted our response to the 120-day letter from the EMA on or prior to September 14, 2018 in accordance with the Amendment, both in exchange for the elimination of an aggregate of €2.0 million (approximately $2.3 million) of regulatory milestones provided for in the Purchase Agreement that are potentially payable in 2019, at the earliest | |||||||||
| Estimated Selling Price | $ 1,400,000 | |||||||||
| Revenue Recognition Milestone Method Payment | $ 1,100,000 | $ 157,000 | ||||||||
| Revenue from Contract with Customer, Including Assessed Tax | 535,000 | $ 0 | $ 0 | |||||||
| Amount Received Under Amendment To Purchase Agreement | $ 1,100,000 | € 950,000 | ||||||||
| Convertible Debt | $ 600,000 | € 550,000 | ||||||||
| Share Price | $ / shares | $ 3.42 | |||||||||
| Scenario, Forecast [Member] | ||||||||||
| Purchase Agreement [Line Items] | ||||||||||
| Revenue from Contract with Customer, Including Assessed Tax | $ 104,000 | |||||||||
| Intellectual Property [Member] | ||||||||||
| Purchase Agreement [Line Items] | ||||||||||
| Finite-Lived Intangible Assets, Translation and Purchase Accounting Adjustments | $ 1,000,000 | |||||||||
| Convertible Debt [Member] | ||||||||||
| Purchase Agreement [Line Items] | ||||||||||
| Debt Instrument, Interest Rate Terms | In the event the EMA has not granted marketing approval by December 31, 2019, the Convertible Loan will become due and payable, together with accrued interest at the rate of one-month LIBOR (to the extent in excess of 1.10%) plus 9.50% per annum. | |||||||||